Clinical TrialSingle-armKetamineCompleted
IV Ketamine for Adolescents with Treatment-Resistant Depression: Open-Label Pilot (Cullen 2018, University of Minnesota)
Single-arm open-label Phase 2 pilot listed on ClinicalTrials.gov (NCT02078817). Participants: adolescents aged 12-18 with MDD and TRD. Intervention: six IV ketamine infusions at 0.5 mg/kg over 40 minutes over 2 weeks. The published paper defines percent change in CDRS-R from baseline to 1 day after the final infusion as the primary outcome; CTG lists CGI responder count at 2 weeks as the registered primary outcome.
Target Enrollment
13 participants
Study Type
interventional
Design
Non-randomized
Registry
Study Arms & Interventions
Ketamine
experimentalSix serial infusions of intravenous ketamine administered over 2 weeks.
Interventions
- Ketamine0.5 mg/kgvia IV• six infusions over 2 weeks• 6 doses total
Initial dosing for first 5 participants was based on ideal body weight, then switched to actual body weight for subsequent participants.
Study Details
- StatusCompleted
- Typeinterventional
- DesignNon-randomized
- Target Enrollment13 participants
- TimelineStart: 2016-01-01End: 2018-01-01
- Compound